Table 4.

Hierarchical regression analysis for the mean Benefit Finding Scale score (n = 3297)

Step		B	SE B	β	Adj. R2	ΔR2
1	Sociodemographics				0.048	0.049***
	Age at survey†	0.015	0.005	0.095**
	School education†	− 0.125	0.010	− 0.212***
	Partnership‡	0.051	0.050	0.017
	Children†	0.022	0.017	0.022
	Age at diagnosis†	− 0.022	0.005	− 0.135***
2	+ Clinical variables				0.051	0.005*
	Age at survey†	0.013	0.005	0.085**
	School education†	− 0.122	0.010	− 0.208***
	Partnership‡	0.051	0.050	0.017
	Children†	0.024	0.017	0.024
	Age at diagnosis†	− 0.021	0.005	− 0.128***
	Second primary cancer‡	− 0.033	0.051	− 0.011
	Family history of PCa‡	− 0.063	0.035	− 0.030
	PSA level at diagnosis†	− 0.001	0.001	− 0.010
	Biochemical recurrence during FU‡	0.083	0.050	0.039
	Biochemical recurrence at survey‡	− 0.001	0.058	0.000
	Ongoing treatment at survey‡	0.101	0.057	0.034
3	+ Psychosocial variables				0.96	0.046***
	Age at survey†	0.014	0.005	0.092**
	School education†	− 0.107	0.010	− 0.181***
	Partnership‡	0.041	0.049	0.014
	Children†	0.036	0.016	0.037*
	Age at diagnosis†	− 0.018	0.005	− 0.113***
	Second primary cancer‡	− 0.007	0.050	− 0.002
	Family history of PCa‡	− 0.044	0.035	− 0.021
	PSA level at diagnosis†	− 0.001	0.001	− 0.016
	Biochemical recurrence during FU‡	0.049	0.049	0.024
	Biochemical recurrence at survey‡	0.006	0.057	0.002
	Ongoing treatment at survey‡	0.089	0.056	0.030
	Depressive symptoms (PHQ-2) †	− 0.044	0.020	− 0.051*
	Anxiety symptoms (GAD-2) †	0.041	0.022	0.044
	Perceived severity †	0.220	0.018	0.217***

SE, standard error; PCa, prostate cancer; PSA, prostate specific antigen; FU, follow-up; PHQ-2, Patient Health Questionnaire-2; GAD-2, Generalized Anxiety Disorder-2 scale; Perceived severity, perceived severity of the disease experience

^†considered continuous variable; ‡scored 0 = no, 1 = yes

*p < 0.05, **p < 0.01, ***p < 0.001